Ibuprofen_15687-27-1_DataSheet_MedChemExpress
palbociclib的全部数据
Home·Pfizer’s Potential Mega-Blockbuster Breast Cancer Drug 辉瑞口服乳腺癌药物帕博西尼(palbociclib)Pfizer’s PotentialMega-Blockbuster Breast Cancer Drug 辉瑞口服乳腺癌药物帕博西尼(palbociclib)2015年9月5日辉瑞公司的口服乳腺癌药物帕博西尼(palbociclib, Ibrance, 帕博西林)能否成为重磅炸弹产品？帕博西尼(Palbociclib)是近来备受关注的也是辉瑞最重要试验药物之一，2015年2月3日FDA提前批准辉瑞CDK4/6双抑制剂Palbociclib （商品名Ibrance）作为一线药物治疗ER阳性、HER2阴性乳腺癌，比原定4月13日的PDUFA日期提前两个多月。
分析人士预计，palbociclib每年销售额最高可达到30亿-50亿美元之多。
在一项2期临床研究中，使晚期乳腺癌患者的无进展生存期(PFS)平均增加一倍，但对患者总生存期(OS)未显示有统计学意义上的明显改善。
据研究人员2014年4月在圣地亚哥举行的美国癌症研究协会会议上发布的最新数据显示，雌激素受体阳性转移性乳腺癌患者在合并使用Palbociclib与抗雌激素药物来曲唑时，其PFS平均为20.2个月，相比之下，单独使用来曲唑的患者其PFS平均为10.2个月。
辉瑞公司决定在今年第三季度根据乳腺癌试验药物Palbociclib的2期临床试验结果即向美国食品药监局（FDA)申请上市批准，Palbociclib（又名PD-0332991）最早进入人们视野的是在2012年圣安东尼奥乳腺癌会议上（SABCS），一经发布就引起行业广泛关注。
Palbociclib是一种口服的细胞周期素依赖性激酶4、6的抑制药物，主要通过调节细胞周期发挥作用。
Palbociclib主要通过抑制CDK4/6活性来阻止细胞由G1期到S期进而抑制DNA的合成。
Trans IT-CRISPR Transfection Reagent 产品说明书
Trans IT-CRISPR® Transfection ReagentCatalog Number T1706Product DescriptionTrans IT-CRISPR is a non-liposomal polymeric transfection reagent for efficient delivery of CRISPR/Cas components. Trans IT-CRISPR allows for simple, fast and efficient delivery of CRISPR DNA, guide RNA and RNP (Cas9-gRNA ribonucleoprotein) complexes to various cell types, including primary cells. Also,Trans IT-CRISPR effectively delivers siRNA duplexes into various cell lines.*Simple protocols for easy optimization in delivering CRISPR/Cas components to cells in DNA, guide RNA and RNP formats.*Efficient delivery to various cell lines, including common cell types and difficult to transfect cell types.Storage/StabilityTrans IT-CRISPR Transfection Reagent is shipped on wet ice. Upon receipt, please store at –20°C. With proper handling and storage, this product remains stable for one year from the date of purchase.Precautions and DisclaimerThis product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices. SIGMA-ALDRICH CRISPR PLASMID DNA TRANSFECTIONTips for Plasmid DNA TransfectionOptimize reaction conditions for different cell types to ensure successful transfections. The suggestions provided in this protocol yield high efficiency plasmid DNA transfection using the Trans IT-CRISPR Transfection Reagent. Table 1 lists recommended starting conditions depending on culture vessel size. • Cell density at transfection:The recommended cell density for most cell types is ≥ 80% confluence. Determine the optimal cell density for each cell type in order to maximize transfection efficiency. Split cells 18–24 hours before transfection to ensure that the cells are actively dividing and reach the appropriate cell density at the time of transfection.• DNA purity:Use highly purified, sterile, and contaminant-free DNA for transfection. Plasmid DNA preparations that are endotoxin-free and have A260/280 absorbance ratio of 1.8–2.0 are desirable. DNA prepared using mini-prep kits is not recommended as it might contain high levels of endotoxin.• Ratio of Trans IT-CRISPR to DNA: Determine the best Trans IT-CRISPR: DNA ratio for each cell type. Start with 3 µl of Trans IT-CRISPR per 1 µg of DNA. Vary the amount of Trans IT-CRISPR from 2–6 µl per 1 µg DNA to find the optimal ratio. Table 1 provides recommended starting conditions.• Complex formation conditions: Prepare Trans IT-CRISPR: DNA complexes in serum-free growth medium. Recommendation: Opti-MEM TM I Reduced-Serum Medium, without antibiotics. • Cell culture conditions:Culture cells in the appropriate medium, with or without serum. There is no need to perform a medium change to remove the transfection complexes.• Presence of antibiotics:Transfection complexes can be added directly to cells grown in complete culture medium containing serum and low levels of antibiotics (0.1–1X final concentration ofpenicillin/streptomycin mixture). Do not include antibiotics during the complex formation step.• Post-transfection incubation time : Determine the best incubation time post-transfection for each cell type. The optimalincubation time is generally 24–72 hours, but will vary depending on the goal of the experiment, nature of the plasmid used, and cell doubling time.Sigma-Aldrich CRISPR Plasmid DNATransfection Protocol per Well of a 6-Well Plate in Human Osteosarcoma (U2OS) Cells and a Human Immortalized Liver Cell Line (HepaRG)The following procedure describes how to perform plasmid DNA transfections using the Trans IT-CRISPR transfection reagent in 6-well plates. The surface areas of other culturevessels are different and transfections must be scaled accordingly (see Table 1 as an example).Plate Cells∙ Approximately 18-24 hours beforetransfection, plate cells in 2.5 mlcomplete growth medium per well in a 6-well plate. For most cell types, cultures should be ≥ 80% confluent at the time of transfection.o For adherent U2OS andHepaRG cells : Plate at a density of 2.5 x 105 cells/ml.o For other adherent cells : Platecells at a density of 0.8–3.0 × 105 cells/ml.∙ Incubate cell cultures overnight.Prepare Trans IT-CRISPR: DNA CRISPRcomplexes (Immediately before transfection)∙ Warm Trans IT-CRISPR to roomtemperature and vortex gently before using.∙ Place 250 µl of Opti-MEM ® I Reduced –Serum Medium in a sterile tube.∙ Add between 2 – 4 µg of Sigma-AldrichCRISPR plasmid DNA.Table 1. Recommended starting conditions for DNA transfections with Trans IT-CRISPR Transfection Reagent DNACulture vessel 96-well48-well 24-well12-well6-well10-cm dishT75 flaskSurface area0.35 cm 2 1 cm 2 1.9 cm 2 3.8 cm 2 9.6 cm 2 59 cm 2 75 cm 2 Complete growth medium92 µl 263 µl 0.5 ml 1 ml 2.5 ml 15.5 ml 19.7 ml Serum-free medium 9 µl 26 µl 50 µl 100 µl 250 µl 1.5 ml 1.9 ml DNA (1 µg/µl stock)0.1 µl0.26 µl0.5 µl1 µl2.5 µl15 µl19 µlFor the all-in-one Sigma-Aldrich CRISPR FP vectors, add 4 µg of plasmid. For the dual vector Sigma-Aldrich CRISPR plasmids, add 2 µg of U6-gRNA only plasmid and 2 µg of CMV-Cas9-FP only plasmid.∙ Pipet gently to mix completely.∙ Add 3-6 µl Trans IT-CRISPR (1.5 µl ofTrans IT-CRISPR per 1 µg of CRISPR plasmid DNA) to the diluted DNA mixture.∙ Pipet gently to mix completely.∙ Incubate at room temperature for 15-30minutes to allow sufficient time for complexes to form.Distribute the complexes to cells in complete growth medium∙ Add the Trans IT-CRISPR: DNAcomplexes drop-wise to different areas of the wells.∙ Gently rock the culture vessel back andforth and from side-to–side to evenly distribute the Trans IT-CRISPR: DNA complexes.∙ Incubate for 48 hours. It is notnecessary to replace the complete growth medium with fresh medium. ∙ Harvest cells and assay as required.Delivery of purified recombinant Cas9 protein and guide RNA Ribonucleoprotein Complexes (RNPsRecent papers have shown the efficacy of delivering the CRISPR components by combining purified Cas9 protein-guide RNA ribonucleoprotein (RNP) complexes. Trans IT-CRISPR transfection reagent has been tested in U2OS and HepaRG cells for efficient delivery of Cas9-gRNA RNP complexes to induce efficient site-specific mutations at targeted genomic regions. Protocols for both IVT gRNA and synthetic crRNA & tracrRNA are listed below. Prepare Trans IT-CRISPR: In Vitro Transcribed gRNA/Cas9 Protein CRISPR complexes (Immediately before transfection) Use between a 1.2 and 5 molar excess of in vitro transcribed RNA to Cas9 protein.∙Pipet between 1.2 and 5 µg of in vitro transcribed RNA to a sterile tube on ice.∙Add between 5 and 10 µg of Cas9protein to the in vitro transcribed RNA,mix gently and incubate on ice for 30minutes.∙ Warm Trans IT-CRISPR to roomtemperature and vortex gently beforeusing.∙Place 250 µl of Opti-MEM TM I Reduced –Serum Medium to the Cas9Ribonucleoprotein (RNP) sterile tube.∙Add between 5 - 6.25 µl of Trans IT-CRISPR to the diluted Cas9 RNP.∙Pipet gently to mix completely.∙Incubate at room temperature for 15 –30 minutes to allow sufficient time forcomplexes to form.Prepare Trans IT-CRISPR: SygRNA™Synthetic crRNA & tracrRNA /Cas9Protein CRISPR complexes (Immediatelybefore transfection)Use a between a 1 and 5 molar excess of SygRNA™ synthetic crRNA & tracrRNA to Cas9 protein.∙Pipet between 30 and 300 pmol each of synthetic crRNA and tracrRNA into asterile tube on ice (typically between 1.5and 15 µl of 20 µM synthetic RNA stocksolutions).∙Add between 5 and 10 µg of Cas9protein (30 to 60 pmol) to the syntheticcrRNA and tracrRNA, mix gently andincubate on ice for 30 minutes.∙ Warm Trans IT-CRISPR to roomtemperature and vortex gently beforeusing.∙Place 250 µl of Opti-MEM I Reduced –Serum Medium to the Cas9 RNP steriletube.∙Add between 5 - 6.25 µl of Trans IT-CRISPR to the diluted Cas9 RNP.∙Pipet gently to mix completely.∙Incubate at room temperature for 15 –30 minutes to allow sufficient time forcomplexes to form.Distribute the complexes to cells in complete growth medium∙ Add the Trans IT-CRISPR: RNPcomplexes drop – wise to different areasof the wells.∙Gently rock the culture vessel back-and- forth, and from side-to–side to evenlydistribute the Trans IT-CRISPR: RNPcomplexes.∙Incubate for 24-72 hours. It is notnecessary to replace the completegrowth medium with fresh medium.∙Harvest cells and assay as required.The Trans IT-CRISPR transfection reagent can also be used to deliver siRNA duplexes for gene silencing experiments.Increase knockdown efficiency by using Trans IT-CRISPR transfection reagent.MISSION® siRNA TRANSFECTIONImportant Tips for Optimal siRNA TransfectionOptimize reaction conditions for each cell type to ensure successful transfections. The suggestions below yield high efficiency knockdown of target gene expression using the Trans IT-CRISPR Transfection Reagent. For siRNA, please refer to Table 2 for recommended starting conditions depending on culture vessel size.• Cell density: The recommended cell density for most cell types is ≥ 80% confluence. Determine the optimal cell density for each cell type in order to maximize transfection efficiency. Plate the cells 18–24 hours before transfection to ensure that the cells are actively dividing and reach the appropriate cell density at the time of transfection.• Volume of Trans IT-CRISPR : Each cell type responds differently to a given transfection reagent.As a starting point, test 7.5 µl of Trans IT-CRISPR per well of a 6-well plate. For further optimization, test three amounts of Trans IT-CRISPR, e.g. 5 µl, 7.5 µl, and 10 µl per well of a 6-well plate.• siRNA dilution : Dilute siRNA using the manufacturer’s recommended buffer.Alternatively, use 100 mM NaCl in 50 mM Tris, pH 7.5, made with RNase-free water. Do not use water alone to dilute siRNA, as this may result in denaturation of the siRNA at low concentrations.• siRNA concentration : siRNA used fortransfection should be highly pure, sterile, and the correct sequence. Depending on the type of experiment, the optimal final siRNAconcentration for transfection is typically within the range of 10–50 nM. As a starting point, we recommend 25 nM siRNA (final concentration in well).• Proper controls : We recommendtransfecting a non-targeting siRNA (Sigma-Aldrich MISSION® siRNA Universal Negative Controls SIC001 or 6-FAM-labeled SIC007) to verify that the gene expression knockdown or phenotype is attributed to the gene-specificsiRNA. Additionally, independent transfection of three to four siRNA duplexes targeting aparticular gene minimizes the possibility that the observed phenotype is due to off-target effects.• Complex formation conditions : Prepare Trans IT-CRISPR: siRNA complexes in serum-free growth medium. Recommended: Opti-MEM TM I Reduced-Serum Medium.• Cell culture conditions : Culture cells in the appropriate medium, with or without serum There is no need to perform a medium change to remove the transfection complexes. Trans IT-CRISPR yields improved transfectionefficiencies when transfections are performed in complete growth medium (instead of serum-free medium) without a post-transfection medium change.• Presence of antibiotics : Antibiotics will inhibit transfection complex formation andtherefore should be excluded from the complex formation step. Transfection complexes can be added to cells grown in complete culturemedium containing low levels of antibiotics (0.1–1X final concentration of penicillin/streptomycin mixture).• Transfection incubation time : The optimal incubation time can be determined empirically by testing a range from 24–72 hours post-transfection, depending on the stability of the target mRNA and its encoded protein. When quantifying knockdown efficiencies at the mRNA level, assaying at 24 hours post-transfection is often sufficient. When quantifying knockdown efficiencies at the protein level, longer post-transfection incubation may be necessary particularly if the target protein has a long cellular half-life.Table 2. Recommended starting conditions for siRNA transfections with Trans IT-CRISPR Transfection Reagent siRNA Culture vessel 96-well48-well24-well12-well6-well 10-cm dish T75 flask Surface area0.35 cm 2 1 cm 2 1.9 cm 2 3.8 cm 2 9.6 cm 2 59 cm 2 75 cm 2 Complete growth medium92 µl 263 µl 0.5 ml 1 ml 2.5 ml 15.5 ml 19.7 ml Serum-free medium 9 µl 26 µl 50 µl 100 µl 250 µl 1.5 ml 1.9 ml MISSION® siRNA (10 µM stock) 25 nM final0.25 µl 0.7 µl 1.4 µl 2.8 µl 6.8 µl 42.5 µl 54 µl TransIT-CRISPR0.3 µl0.78 µl1.5 µl3 µl7.5 µl45 µl57 µlRelated Products∙CRISPR Custom Plasmid and RNA, Catalog Number CRISPR/crisprs∙ CRISPR CMV-CAS9-2A-GFP Plasmid, Catalog Number CAS9GFPP∙ CRISPR CMV-CAS9D10A-2A-GFP Plasmid, Catalog Number CAS9D10AGFPP∙CRISPR Universal Negative Control 1, Catalog Number CRISPR06∙ Custom SygRNA TM, Catalog NumberVC40003∙SygRNA™ Cas9 Synthetic tracrRNA,Catalog Number TRACRRNA05N-5NMOL∙Cas9-NLS from Streptococcus pyogenes, Catalog Number CAS9PROT∙Enhanced specificity Cas9-NLS fromStreptococcus pyogenes, Catalog NumberESPCAS9PRO∙Cas9 Recombinant protein fromStreptococcus pyogenes, Catalog NumberTGEN-CP∙Cas9 Nickase Recombinant protein from Streptococcus pyogenes, Catalog NumberTGEN-CNP∙ MISSION® siRNA duplexes, predesigned and custom/siRNA∙ MISSION® siRNA Universal NegativeControl #1, Catalog Number SIC001∙MISSION® siRNA Fluorescent Universal Negative Control #1, 6-FAM, CatalogNumber SIC007∙MISSION TRC 3 – LentiORF Collection /lentiorf Opti-MEM is a registered trademark of Life Technologies, Inc.SygRNA is a trademark and MISSION is a registered trademark of Sigma-Aldrich Co. LLC.MIRUS, TransIT and Trans IT-CRISPR are registered trademarks of Mirus Bio LLC.JW,PA,PHC 07/17-2©2017 Sigma-Aldrich Co. LLC. All rights reserved. SIGMA-ALDRICH is a trademark of Sigma-Aldrich Co. LLC, registered in the US and other countries. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see product information on the Sigma-Aldrich website at and/or on the reverseside of the invoice or packing slip.。
CAS号1668553-26-1_A-1210477使用方法MedBio
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11288
TC ASK 10
TC ASK 10
1005775-56-3
10mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11343
棉酚
Gossypol
303-45-7
10mM (in 1mL DMSO)
≥98%
A-1210477（10μM）减少了与MCL-1抗体共免疫沉淀的BIM的量，并在多种癌细胞系（包括乳腺癌细胞系HCC-1806）中引发MCL-1升高。A-1210477抑制MCL-1-NOXA相互作用，IC50约为1μM，而对BCL-2-BIM或BCL-XL-BCL-XS相互作用没有影响。NSCLC细胞系H2110和H23对A-1210477敏感，细胞活力IC50 <10μM，证实A-1210477可以杀死MCL-1依赖的细胞系[1]。在短暂（4小时）暴露后，A-1210477在H929细胞中诱导广泛的浓度依赖性细胞凋亡。A-1210477与MCL-1相互作用，其Kd为约740nM。A-1210477（10μM）以DRP-1依赖性方式诱导广泛的线粒体片段化[2]。A-1210477以剂量依赖性方式上调BRAF突变体CRC细胞和黑素瘤细胞系A375中的MCL-1表达。A-1210477从MCL-1释放BAK，而cobimetinib诱导BAX活化所需的BIM [3]。A-1210477（0,5,10和15μM）对细胞活力的影响极小，但对BCL2High NHL细胞系的导管作用基本敏感[4]。
盐酸诺拉曲塞
EL-102_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :EL-102Catalog No. :HY-16187CAS No. :1233948-61-21.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:EL 102; EL102Formula:C19H16N2O3S2Molecular Weight:384.47CAS No. :1233948-61-24. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
人髓磷脂碱性蛋白(MBP)说明书
人髓磷脂碱性蛋白(MBP)酶联免疫酶联免疫分析分析分析试剂试剂盒使用说明书盒使用说明书盒使用说明书本试剂盒仅供研究使用。
检测范围检测范围：： 96T100pg/ml-4000pg/ml使用目的使用目的：：本试剂盒用于测定人血清、血浆及相关液体样本中髓磷脂碱性蛋白(MBP)含量。
实验原理本试剂盒应用双抗体夹心法测定标本中人髓磷脂碱性蛋白(MBP)水平。
用纯化的人髓磷脂碱性蛋白 (MBP)抗体包被微孔板，制成固相抗体，往包被单抗的微孔中依次加入髓磷脂碱性蛋白(MBP)，再与HRP 标记的髓磷脂碱性蛋白 (MBP)抗体结合，形成抗体-抗原-酶标抗体复合物，经过彻底洗涤后加底物TMB 显色。
TMB 在HRP 酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。
颜色的深浅和样品中的髓磷脂碱性蛋白(MBP)呈正相关。
用酶标仪在450nm 波长下测定吸光度（OD 值），通过标准曲线计算样品中人髓磷脂碱性蛋白 (MBP)浓度。
试剂盒组成 1 30倍浓缩洗涤液 20ml ×1瓶 7 终止液 6ml ×1瓶 2 酶标试剂 6ml ×1瓶 8 标准品（8000pg/ml ）0.5ml ×1瓶 3 酶标包被板 12孔×8条 9 标准品稀释液 1.5ml ×1瓶 4 样品稀释液 6ml ×1瓶 10 说明书 1份 5 显色剂A 液 6ml ×1瓶 11 封板膜 2张 6显色剂B 液6ml ×1/瓶12密封袋1个标本标本要求要求1．标本采集后尽早进行提取，提取按相关文献进行，提取后应尽快进行实验。
若不能马上进行试验，可将标本放于-20℃保存，但应避免反复冻融2．不能检测含NaN3的样品，因NaN3抑制辣根过氧化物酶的（HRP ）活性。
操作步骤1. 标准品的稀释：本试剂盒提供原倍标准品一支，用户可按照下列图表在小试管中进行稀释。
抗体公司
赛信通（上海）生物试剂有限公司
上海市浦东南路1101号远东大厦514室，200120 info@cst www.cst 2158356288 公司总部: 美国
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privatelyowned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activationstate and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine. 总引用数为4670，来自于1966篇文章。最常引用的试剂包括： Akt, ERK2, ERK1, p38, Akt1。
AbD Serotec (BioRad)
BP2015英国药典索引
page numbers in bold type relate to monograph titles Index V-A797IndexPage numbers in bold type relate to monograph titles.Pages–Vol I:i–xxxii,(Preliminaries and Introduction)1–1280,(General Notices and Monographs)Pages–Vol II:i–viii,(Preliminaries)1–1220,(General Notices and Monographs)Pages–Vol III:i–viii,(Preliminaries)1–1238,(General Notices and Monographs)Pages–Vol IV:i–viii,(Preliminaries)1–754,(General Notices and Monographs)Pages–Vol V:i–viii,(Preliminaries)1–34,(General Notices)S1–S144,(Spectra)A1–A796,(Appendices;Supplementary Chapters)AAbacavir,V-S4Abacavir Oral Solution,III-85 Abacavir Sulfate,I-39Abacavir Tablets,III-86 Abbreviated,V-598Adjectives,V-598Anions,V-598Cations,V-598Preparations,V-598Titles of Monographs,V-598 Abbreviated Titles,Status of,I-7,II-7, III-7,IV-7,V-7Abbreviations and symbols,I-30,II-30, III-30,IV-30,V-30Abnormal Toxicity,Test for,V-409 About,definition of,I-5,II-5,III-5,IV-5,V-5Absence of Mycoplasmas,Test forV-487Absolute Ethanol,V-A61Absolute Ethanol R1,V-A62 Absorbent Cotton,IV-743Absorbent Viscose Wadding,IV-744 Absorption spectrophotometry,infrared, V-162Absorption Spectrophotometry, Ultraviolet and Visible,V-169 Acacia,I-41,V-A19Acacia Solution,V-A19Acacia Spray-dried,I-42 Acamprosate Calcium,I-43 Acanthopanax Bark,IV-49 Acarbose,I-44Accuracy,V-674Acebutolol Capsules,III-87 Acebutolol Hydrochloride,I-46,V-S5, V-A19Acebutolol Tablets,III-88 Aceclofenac,I-48Acemetacin,I-50Acenocoumarol,I-52,V-S5 Acenocoumarol Tablets,III-88 Acesulfame Potassium,I-52Acetal,V-A19Acetaldehyde,V-A19Acetaldehyde Ammonia Trimer Trihydrate,V-A20Acetaldehyde Standard Solution(100ppm C2H4O),V-A148 Acetaldehyde Standard Solution(100ppm C2H4O)R1,V-A148 Acetamide,V-A20Acetate Buffer pH2.8,V-A152 Acetate Buffer pH2.45,V-A152 Acetate Buffer pH3.4,V-A152 Acetate Buffer pH3.5,V-A152 Acetate Buffer pH3.7,V-A152 Acetate Buffer pH4.4,V-A152 Acetate Buffer pH4.6,V-A152 Acetate Buffer pH5.0,V-A152 Acetate Buffer pH6.0,V-A152 Acetate Buffer Solution pH4.7R1,V-A153Acetate Buffer Solution pH4.4,see Acetate Buffer pH4.4Acetate Buffer Solution pH4.6,see Acetate Buffer pH4.6Acetate Buffer Solution pH6.0,seeAcetate Buffer pH6.0Acetate Buffer Solution pH4.4,V-A152Acetate Buffer Solution pH4.5,V-A152Acetate Buffer Solution pH4.7,V-A152Acetate Buffer Solution pH5.0,V-A153Acetate Buffer Solution pH6.0,V-A153Acetate–edetate Buffer Solution pH5.5,V-A153Acetates,Reactions of,V-266Acetazolamide,I-54,V-S5Acetazolamide Oral Suspension,III-89Acetazolamide Tablets,III-90Acetic Acid,V-A20Acetic Acid(6per cent),I-56Acetic Acid(33per cent),I-56Acetic Acid,Anhydrous,V-A20Acetic Acid,Deuterated,V-A50Acetic Acid,Dilute,V-A20Acetic Acid,Dilute,see Acetic Acid(6per cent)Acetic Acid,Glacial,I-55,V-A20Acetic Acid in Synthetic Peptides,Determination of,V-299Acetic Acid VS,V-A142Acetic Acid,see Acetic Acid(33per cent)Acetic Anhydride,V-A20Acetic Anhydride Solution R1,V-A20Acetic Anhydride–Dioxan Solution,V-A20Acetic Anhydride–Sulfuric Acid Solution,V-A20Acetic Anhydride–Sulphuric AcidSolution,see Acetic Anhydride–SulfuricAcid SolutionAcetic Bromine Solution,V-A34Acetone,I-57,V-A20Acetone,Deuterated,V-A50Acetone Solution,Buffered,V-A153Acetone-dried Ox Brain,V-A98Acetonitrile,V-A20Acetonitrile for Chromatography,V-A20Acetonitrile R1,V-A20Acetoxyvalerenic Acid,V-A20Acetyl Chloride,V-A20Acetyl Groups,Reactions of,V-266Acetyl Salicylic Acid see AspirinAcetyl Value,Determination of,V-317Acetylacetamide,V-A20Acetylacetone,V-A20Acetylacetone Reagent R1,V-A20Acetylacetone Reagent R2,V-A204-Acetylbiphenyl,V-A20O-Acetyl Groups in PolysaccharideVaccines,V-467N-Acetyl-e-caprolactam,V-A20Acetylcholine Chloride,I-58,V-A20Acetylcysteine,I-59,V-S6Acetylcysteine Eye Drops,III-90Acetylcysteine Injection,III-91Acetyldigoxin,I-61b-Acetyldigoxin see AcetyldigoxinAcetyleugenol,V-A20N-Acetylglucosamine,V-A21Acetyl-11-keto-b-boswellic Acid,V-A21N-Acetyl-L-cysteine,V-A20N-Acetylneuraminic Acid,V-A21Acetylsalicylic Acid Tablets,see AspirinTabletsN-Acetyltryptophan,V-A21N-Acetyltryptophan see AcetyltryptophanAcetyltryptophan,I-63Acetyltyrosine,I-65N-Acetyltyrosine see AcetyltyrosineAcetyltyrosine Ethyl Ester,V-A21Acetyltyrosine Ethyl Ester,0.2M,V-A21Aciclovir,I-67Aciclovir Cream,III-93Aciclovir Eye Ointment,III-94Aciclovir Infusion,III-95Aciclovir Intravenous Infusion,seeAciclovir Infusion,Aciclovir Oral Suspension,III-97Aciclovir Sodium for Infusion,III-95Aciclovir Sodium for IntravenousInfusion,see Aciclovir Sodium forInfusion,Aciclovir Tablets,III-98Aciclovir Tablets,Dispersible,III-99Acid Blue92,V-A21Acid Blue92Solution,V-A21Acid Blue83,V-A21Acid Blue93Solution,V-A21Acid Blue90,V-A21Acid Gentian Mixture,IV-197Acid Gentian Oral Solution,IV-197Acid Potassium IodobismuthateSolution,V-A108Acid Value,V-317Acid/base Indicators,V-789Acid-base titrations,V-788Acidified Chloroform,V-A41Acidified Dichloromethane,V-A52Acidified Methanol,V-A85Acidified Methylene Chloride,seeAcidified DichloromethaneAcid-insoluble Ash,Determination of,V-336Acid-washed Diatomaceous Support,V-A51Acitretin,I-69Acitretin Capsules,III-100Acknowledgements,I-xxviiAcrylamide,V-A21Acrylamide/bisacrylamide(29:1)Solution,30per cent,V-A21Acrylamide/bisacrylamide(36.5:1)Solution,30per cent,V-A21Acrylic Acid,V-A21Actein,V-A21Acteoside,V-A21Action and Use Statement,Status of,I-17,II-17,III-17,IV-17,V-17Activated Acid Aluminium Oxide,V-A23Activated Attapulgite,I-220Activated Charcoal,I-496,V-A40Activated Zinc,V-A140Active Moiety,V-651Adamantane,V-A21Adapalene,I-71Adapalene Cream,III-101Adapalene Gel,III-103Additions,List of,I-xxviiiAdditions,List of Monographs,I-xxiiAdditives,Plastic,V-592Adenine,I-72,V-A21Adenosine,I-73,V-A21Adipic Acid,I-75,V-A21Adrenaline,V-A21Adrenaline/Epinephrine,I-76page numbers in bold type relate to monograph titles Index V-A799Adrenaline Acid Tartrate,V-A21 Adrenaline Acid Tartrate/Epinephrine Acid Tartrate,I-77Adrenaline and Cocaine Intranasal Solution,III-107Adrenaline(Epinephrine),V-S6 Adrenaline Eye Drops,Epinephrine Eye Drops,Neutral,III-104Adrenaline Eye Drops/Epinephrine Eye Drops,III-104Adrenaline Injection,Bupivacaine and, III-220Adrenaline Injection,Dilute(1in10,000),III-106Adrenaline Injection,Lidocaine and,III-751Adrenaline Injection/Epinephrine Injection,III-105Adrenaline Solution/Epinephrine Solution,III-106Adrenaline Tartrate see Adrenaline Acid TartrateAdrenaline TartrateInjection/Epinephrine Tartrate Injection,III-105Adrenaline TartrateSolution/Epinephrine Tartrate Solution,III-106Adrenalone Hydrochloride,V-A21 Adsorbed Diphtheria and Tetanus Vaccine,IV-537Adsorbed Diphtheria and Tetanus Vaccine for Adults and Adolescents, see Adsorbed Diphtheria and Tetanus Vaccine(adsorbed,Reduced Antigen(s) Content)Adsorbed Diphtheria,Tetanus and Pertussis(Acellular Component) Vaccine,IV-541Adsorbed Diphtheria,Tetanus,Pertussis (Acellular Component)and Haemophilus Type b Conjugate Vaccine,IV-545Adsorbed Diphtheria,Tetanus,Pertussis (Acellular Component)and Hepatitis B(rDNA)Vaccine,IV-547 Adsorbed Diphtheria,Tetanus,Pertussis (Acellular Component)and Inactivated Poliomyelitis Vaccine,IV-548Adsorbed Diphtheria Vaccine,IV-534 Adsorbed Diphtheria Vaccine for Adults and Adolescents,see Diphtheria Vaccine (Adsorbed,Reduced Antigen Content) Adsorbed Pertussis Vaccine(Acellular Component),IV-604Adsorbed Pertussis Vaccine(Acellular, Co-purified),IV-605Adsorbed Tetanus Vaccine,IV-633 Adsorbed Vaccines,Aluminium in,V-463Adsorbed Vaccines,Calcium in,V-464 Adsorption,Gas,Specific Surface Area By(2.9.26.)(5.8.),V-701Aescin,V-A22Aflatoxin B1,V-A22Aflatoxin B,in Herbal Drugs, Determination of,V-341Agar,I-79,V-A22Agarose for Chromatography,V-A22Agarose for Chromatography,Cross-linked,V-A22Agarose for Chromatography R1,Cross-linked,V-A22Agarose for Electrophoresis,V-A22Agarose/Cross-linked Polyacrylamide,V-A22Agarose-DEAE for Ion ExchangeChromatography,V-A22Agnus Castus Fruit,IV-50Agrimony,IV-52Air,Medical,I-78Air,Medicinal see Medical AirAir Permeability,Specific Surface Areaby,V-505Air,Synthetic,I-81Air,Synthetic Medicinal see Synthetic AirAlanine,I-83,V-A22ß-Alanine,see3-Aminopropionic AcidAlbendazole,I-84Albumin,Bovine,V-A22Albumin,Bovine R1,V-A22Albumin,Human,V-A22Albumin Solution,IV-467Albumin Solution,Human,V-A22Albumin Solution R1,Human,V-A22Alchemilla,IV-53Alcohol(20per cent),I-900Alcohol(25per cent),I-900Alcohol(45per cent),I-900Alcohol(50per cent),I-900Alcohol(60per cent),I-900Alcohol(70per cent),I-900Alcohol(80per cent),I-900Alcohol(90per cent),I-900Alcohol,Aldehyde-free,see Ethanol(96%),Aldehyde-freeAlcoholic Calcium Standard Solution(100ppm Ca),V-A149Alcoholic DimethylaminobenzaldehydeSolution,V-A55Alcoholic Hydroxylamine Solution,V-A74Alcoholic Iodine Solution,III-696,V-A75Alcoholic Potassium Hydroxide,2M,V-A108Alcoholic Potassium Hydroxide,seePotassium Hydroxide VS,EthanolicAlcoholic Potassium Hydroxide Solution,V-A108Alcoholic Potassium Hydroxide SolutionR1,V-A108Alcoholic Solution of Sulfuric Acid,V-A128Alcoholic Sulfuric Acid,0.25M,V-A128Alcoholimetric Tables,V-687Alcohol,see Ethanol(96%)Alcuronium Chloride,I-85Aldehyde Dehydrogenase,V-A22Aldehyde Dehydrogenase Solution,V-A22Aldehyde-free alcohol,see Ethanol(96%),Aldehyde-freeAldehyde-free Ethanol(96%),V-A62Aldehyde-free Methanol,V-A85Aldehydes,Determination of,V-321Aldrin,V-A22Alendronate Sodium Tablets,seeAlendronic Acid TabletsAlendronic Acid Tablets,III-109Aleuritic Acid,V-A22Alexandrian Senna Fruit,IV-362Alfacalcidol,I-87Alfadex,I-88Alfentanil Hydrochloride,I-89Alfuzosin,V-S7Alfuzosin Hydrochloride,I-91Alfuzosin Tablets,III-111Alfuzosin Tablets,Prolonged-release,III-112Alginate Antacid Oral Suspension,Compound,III-113Alginate Oral Suspension,Raft-forming,III-114Alginate Raft-forming Oral Suspension,III-114Alginic Acid,I-92Alimemazine,V-S7Alimemazine Oral Solution,Paediatric,III-115Alimemazine Tablets,III-116Alimemazine Tartrate,I-93Alizarin S,V-A22Alizarin S Solution,V-A22Alkaline Corallin Solution,V-A46Alkaline Eye Drops,see Hypromellose EyeDropsAlkaline Gentian Mixture,IV-198Alkaline Gentian Oral Solution,IV-198Alkaline Hydroxylamine Solution,V-A74Alkaline Hydroxylamine Solution R1,V-A74Alkaline Potassium Mercuri-iodideSolution,V-A109Alkaline Potassium TetraiodomercurateSolution,V-A109Alkaline Pyrogallol Solution,V-A111Alkaline Sodium Picrate Solution,V-A124Alkaline Tetrazolium Blue Solution,V-A132Alkali-washed Diatomaceous Support,V-A51Alkaloids,Complete Extraction of,V-335Alkaloids,Reactions of,V-266all--Alpha-Tocopherol,II-1051Allantoin,I-94,V-A23Allergen Products,I-95Allium Sativum for HomoeopathicPreparations,IV-427Allopurinol,I-98Allopurinol Oral Suspension,III-117Allopurinol Tablets,III-118all-rac-Alpha-Tocopheryl Acetate,II-1054all-rac-a-Tocopheryl see all-rac-Alpha-Tocopherylall-rac-Tocopheryl Acetate see all-rac-Alpha-Tocopheryl AcetateAlmagate,I-100Almond Oil Ear Drops,III-119Almond Oil,Refined,I-100Almond Oil,Virgin,I-99Almond Oil see Virgin Almond OilAloes,Barbados,IV-53Aloes,Cape,IV-54Alovudine,V-A23Alovudine(18F)Injection,IV-669V-A800IndexAloxiprin,I-102Aloxiprin Tablets,III-119Alpha Tocopheryl Acetate Concentrate (Powder Form),II-1057Alpha Tocopheryl Hydrogen Succinate, II-1058Alpha Tocopheryl Succinate Tablets,III-1164Alphacyclodextrin see Alfadex Alprazolam,I-103Alprenolol Hydrochloride,I-105 Alprostadil,I-107Alteplase for Injection,I-109 Alternative methods,I-20,II-20,III-20, IV-20,V-20Alternative Methods for Control of Microbiological Quality,V-745 Altizide,I-113Alum,I-114Aluminium,V-A23Aluminium Acetate Ear Drops,III-120 Aluminium Chloride,V-A23 Aluminium Chloride Hexahydrate,I-114 Aluminium Chloride Reagent,V-A23 Aluminium Chloride Solution,III-121, V-A23Aluminium Glycinate,I-115 Aluminium Hydroxide and Magnesium Trisilicate Tablets,Chewable,III-776 Aluminium Hydroxide,Dried,I-115 Aluminium Hydroxide Gel,V-A23 Aluminium Hydroxide,Hydrated for Adsorption,I-114Aluminium Hydroxide Oral Suspension, III-121Aluminium Hydroxide Oral Suspension, Magnesium Hydroxide and,III-401 Aluminium Hydroxide Tablets, Chewable,III-122Aluminium Hydroxide Tablets, Magnesium Hydroxide and,III-402 Aluminium Hydroxide Tablets see Chewable Aluminium Hydroxide Tablets,III-122Aluminium in Adsorbed Vaccines,V-463 Aluminium Magnesium Silicate,I-118 Aluminium Nitrate,V-A23Aluminium Oxide,Activated Acid,V-A23Aluminium Oxide,Anhydrous,V-A23 Aluminium Oxide,Basic,V-A23 Aluminium Oxide,Deactivated,V-A23 Aluminium Oxide G,V-A23 Aluminium Oxide,Neutral,V-A23 Aluminium Paste,Compound,III-120 Aluminium Phosphate Gel,I-120 Aluminium Phosphate,Hydrated see Dried Aluminium Phosphate Aluminium Potassium Sulfate,V-A23 Aluminium Potassium Sulphate,see Aluminium Potassium Sulfate Aluminium Powder,I-121Aluminium Salts,Reactions of,V-266 Aluminium Sodium Silicate,I-122 Aluminium Standard Solution(2ppm Al),V-A148Aluminium Standard Solution(10ppm Al),V-A148Aluminium Standard Solution(100ppm Al),V-A148Aluminium Standard Solution(200ppmAl),V-A148Aluminium Stearate,I-123Aluminium Sulfate,I-125,V-A23Aluminium Sulphate,see AluminiumSulfateAlverine Capsules,III-122Alverine Citrate,I-126,V-S7Amantadine Capsules,III-123Amantadine Hydrochloride,I-127Amantadine Oral Solution,III-124Amantidine,V-S8Amaranth S,V-A23Amaranth Solution,V-A23Ambroxol Hydrochloride,I-128Americium-243Spiking Solution,V-A23Amethocaine Eye Drops,see TetracaineEye DropsAmfetamine Sulfate,I-130Amfetamine Sulphote,see AmfetamineSulfate,I-130Amido Black10B Solution,V-A23Amidohexadecylsilyl Silica Gel forchromatography,V-A115Amidotrizoic Acid Dihydrate,I-130Amikacin,I-132Amikacin Injection,III-124Amikacin Sulfate,I-135Amiloride and Furosemide Tablets,seeCo-amilofruse TabletsAmiloride and Hydrochlorothiazide OralSolution,see Co-amilozide Oral SolutionAmiloride and HydrochlorothiazideTablets,see Co-amilozide TabletsAmiloride Hydrochloride,I-138Amiloride Tablets,III-125Amines,Primary Aromatic,Reactions of,V-266Amino Acid Analysis,V-221Amino Acid Analysis(2.2.56.)(5.8.),V-700Amino Acids,Use of Codes for,I-8,II-8,III-8,IV-8,V-8Aminoazobenzene,V-A23Aminobenzoic Acid,I-139,V-A23,V-A244-Aminobenzoic Acid Solution,V-A24(4-Aminobenzoyl)-L-glutamic Acid,V-A244-Aminobutanoic acid,see4-Amino-n-butyric Acid2-Aminobutan-1-ol,V-A24Aminocaproic Acid,I-1402-Amino-5-chlorobenzophenone,V-A24Aminochlorobenzophenone,see2-Amino-5-chlorbenzophenone4-Aminofolic Acid,V-A24Aminoglutethimide,I-141,V-S8Aminoglutethimide Tablets,III-126Aminohexadecylsilyl Silica Gel forChromatography,V-A1156-Aminohexanoic Acid,V-A24p-Aminohippuric Acid,V-A24Aminohippuric Acid Reagent,V-A244-Amino-3-hydroxynaphthalene-1-sulfonic Acid,V-A24Aminohydroxynaphthalenesulfonic AcidSolution,V-A24Aminohydroxynaphthalenesulfonic AcidSolution,Strong,V-A24AminohydroxynaphthalenesulphonicAcid Solution,Strong,seeAminohydroxynaphthalenesulfonic AcidSolution,StrongAminohydroxynaphthalenesulphonicAcid Solution,seeAminohydroxynaphthalenesulfonic AcidSolution4-Amino-3-hydroxynaphthalene-1-sulphonic Acid,see4-Amino-3-hydroxynaphthalene-1-sulfonic AcidAminohydroxynaphthalenesulphonic,Acid,see Aminonaphthalenesulfonic AcidSolution5-Aminoimidazole-4-carboxamideHydrochloride,V-A24cis-Aminoindanol,V-A24Aminomethylalizarindiacetic AcidReagent,V-A24Aminomethylalizarindiacetic AcidSolution,V-A253-Aminomethylalizarin-N,N-diaceticAcid,V-A244-Aminomethylbenzoic acid,V-A253-(Aminomethyl)pyridine,V-A258-Aminonaphthalene-2-sulfonic Acid,V-A25Aminonaphthalenesulfonic AcidSolution,V-A25Aminonaphthalenesulphonic AcidSolution,see AminonaphthalenesulfonicAcid Solution8-Aminonaphthalene-2-sulphonic Acid,see8-Aminonaphthalene-2-sulfonic Acid4-Amino-n-butyric Acid,V-A242-Amino-5-nitrobenzophenone,V-A25Aminonitrobenzophenone,see2-Amino-5-nitrobenzophenone4-Aminophenazone,V-A25Aminophenazone Solution,V-A253-Aminophenol,V-A254-Aminophenol-free Paracetamol,V-A99Aminophylline,I-143Aminophylline Hydrate,I-145Aminophylline Injection,III-128Aminophylline Tablets,III-128Aminophylline Tablets,Prolonged-release,III-129Aminopolyether,V-A253-Aminopropanol,V-A253-Aminopropionic Acid,V-A25Aminopropylmethylsilyl Silica Gel forChromatography,V-A115Aminopropylsilyl Silica Gel forChromatography,V-A115Aminopropylsilyl Silica Gel forChromatography R1,V-A115Aminopyrazolone,see4-AminophenazoneAminopyrazolone Solution,seeAminophenazone Solution3-Aminosalicylic Acid,V-A25Amiodarone,V-S8Amiodarone Concentrate,Sterile,III-130Amiodarone Hydrochloride,I-147Amiodarone Infusion,III-129Amiodarone Intravenous Infusion,seeAmiodarone Infusion,Amiodarone Oral Suspension,III-131Amiodarone Sterile Concentrate,III-130page numbers in bold type relate to monograph titles Index V-A801Amiodarone Tablets,III-132 Amisulpride,I-149,V-S9Amisulpride Oral Solution,III-133 Amisulpride Tablets,III-134 Amitriptyline Embonate,I-150 Amitriptyline Hydrochloride,I-151 Amitriptyline Tablets,III-135 Amlodipine Besilate,I-153 Ammonia,V-A25Ammonia(13N)Injection,IV-672 Ammonia Buffer pH9.5,see Ammonium Chloride Buffer Solution pH9.5 Ammonia Buffer pH10.9,V-A153 Ammonia Buffer pH10.9,Dilute,V-A153Ammonia Buffer pH10.0,V-A153 Ammonia,Chloride-free,V-A25 Ammonia,Concentrated,V-A25 Ammonia,Lead-free,V-A25 Ammonia,Methanolic,V-A25 Ammonia R1,Concentrated,V-A26 Ammonia R1,Dilute,V-A26 Ammonia R2,Dilute,V-A26 Ammonia R3,Dilute,V-A26 Ammonia Solution,Aromatic,III-136 Ammonia Solution,Concentrated see Strong Ammonia SolutionAmmonia Solution,Dilute,III-137 Ammonia Spirit,Aromatic,III-137 Ammoniacal Copper Oxide Solution,V-A46Ammoniacal Silver Nitrate Solution,V-A120Ammoniacal Solution of Copper Tetrammine,V-A46Ammonia-free Water,V-A139 Ammonio Methacrylate Copolymer (Type A),I-155Ammonio Methacrylate Copolymer (Type B),I-1560.5M Ammonium acetate buffer solution pH4.5,see Ammonium acetate buffer pH4.5,0.5M0.01M Ammonium and Cerium Nitrate, see Ammonium Cerium(IV)Nitrate VS 0.1M Ammonium and Cerium Sulfate, see Ammonium Cerium(IV)Sulfate VS Ammonium Acetate,V-A26 Ammonium acetate buffer pH4.5,0.5M, V-A153Ammonium Acetate Solution,V-A26 Ammonium Acetate Solution,Strong,III-137Ammonium and Cerium Nitrate,see Ammonium Cerium(IV)Nitrate Ammonium and Cerium Sulfate,see Ammonium Cerium(IV)Sulfate Ammonium and Cerium Sulphate,see Ammonium and Cerium Sulfate Ammonium Bicarbonate,I-157 Ammonium Bromide,I-158 Ammonium Carbamate,V-A26 Ammonium Carbonate,V-A26 Ammonium Carbonate Buffer Solution pH10.3,0.1M,V-A153Ammonium Carbonate Solution,V-A26 Ammonium Carbonate Solution,Dilute, V-A26Ammonium carbonate solution R1,V-A26Ammonium Cerium(IV)Nitrate,V-A26Ammonium Cerium(IV)Nitrate VS,V-A142Ammonium Cerium(IV)Sulfate,V-A26Ammonium Cerium(IV)Sulfate VS,V-A142Ammonium Cerium(IV)Sulphate VS,seeAmmonium Cerium(IV)Sulfate VSAmmonium Cerium(IV)Sulphate,seeAmmonium Cerium(iv)SulfateAmmonium Chloride,I-159,V-A26Ammonium Chloride Buffer SolutionpH10.0,see Ammonia Buffer pH10.0Ammonium Chloride Buffer SolutionpH10.4,V-A153Ammonium Chloride Buffer SolutionpH10.7,V-A153Ammonium Chloride Buffer SolutionpH9.5,V-A153Ammonium Chloride Buffer SolutionpH10.0,V-A153Ammonium Chloride Mixture,III-137Ammonium Chloride Oral Solution,III-137Ammonium Chloride Solution,V-A26Ammonium Citrate,V-A26Ammonium Citrate Solution,V-A26Ammonium CobaltothiocyanateSolution,V-A26Ammonium DihydrogenOrthophosphate,V-A26Ammonium Formate,V-A26Ammonium Glycyrrhizinate,I-160Ammonium Hexafluorogermanate,V-A26Ammonium Hydrogen Carbonate,V-A26Ammonium Hydrogen Carbonate seeAmmonium BicarbonateAmmonium Ichthosulphonate seeIchthammolAmmonium Iron(II)Sulfate,V-A26Ammonium Iron(II)Sulfate VS,V-A142Ammonium Iron(II)Sulphate VS,seeAmmonium Iron(II)Sulfate VSAmmonium Iron(II)Sulphate,seeAmmonium Iron(ii)SulfateAmmonium Iron(III)Citrate,V-A26Ammonium Iron(III)Sulfate,V-A26Ammonium Iron(III)Sulfate Solution R1,V-A26Ammonium Iron(III)Sulfate Solution R2,V-A26Ammonium Iron(III)Sulfate Solution R5,V-A26Ammonium Iron(III)Sulfate Solution R6,V-A27Ammonium Iron(III)Sulfate VS,V-A142Ammonium Iron(III)Sulphate SolutionR1,see Ammonium Iron(iii)SulfateSolution R1Ammonium Iron(III)Sulphate SolutionR2,see Ammonium Iron(iii)SulfateSolution R2Ammonium Iron(III)Sulphate SolutionR5,see Ammonium Iron(iii)SulfateSolution R5Ammonium Iron(III)Sulphate VS,seeAmmonium Iron(III)Sulfate VSAmmonium Iron(III)Sulphate,seeAmmonium Iron(iii)SulfateAmmonium Mercaptoacetate Solution,V-A27Ammonium Mercurithiocyanate Reagent,V-A27Ammonium Metavanadate,V-A27Ammonium Metavanadate Solution,V-A27Ammonium Molybdate,V-A27Ammonium Molybdate Reagent,V-A27Ammonium Molybdate Reagent R1,V-A27Ammonium Molybdate Reagent R2,V-A27Ammonium Molybdate Solution,V-A27Ammonium Molybdate Solution R2,V-A27Ammonium Molybdate Solution R3,V-A27Ammonium Molybdate Solution R4,V-A27Ammonium Molybdate Solution R5,V-A27Ammonium Molybdate Solution R6,V-A27Ammonium Molybdate-Sulfuric AcidSolution,V-A27Ammonium Molybdate-Sulphuric AcidSolution,see Ammonium Molybdate-Sulfuric Acid SolutionAmmonium Muriaticum,V-609Ammonium Nitrate,V-A27Ammonium Nitrate R1,V-A27Ammonium Oxalate,V-A27Ammonium Oxalate Solution,V-A27Ammonium Persulfate,V-A27Ammonium Persulphate,see AmmoniumPersulfateAmmonium Phosphate,see DiammoniumHydrogen OrthophosphateAmmonium Polysulfide Solution,V-A27Ammonium Polysulphide Solution,seeAmmonium Polysulfide SolutionAmmonium Pyrrolidinedithiocarbamate,V-A27Ammonium PyrrolidinedithiocarbamateSolution,V-A27Ammonium Reineckate,V-A27Ammonium Reineckate Solution,V-A28Ammonium Salts and Salts of VolatileBases,Reactions of,V-267Ammonium Salts Reactions of,V-266Ammonium Standard Solution(1ppmNH4),V-A148Ammonium Standard Solution(2.5ppmNH4),V-A148Ammonium Standard Solution(3ppmNH4),V-A148Ammonium Standard Solution(100ppmNH4),V-A148Ammonium Sulfamate,V-A28Ammonium Sulfate,V-A28Ammonium Sulfide Solution,V-A28Ammonium Sulphamate,see AmmoniumSulfamateAmmonium Sulphate,see AmmoniumSulfateAmmonium Sulphide Solution,seeAmmonium Sulfide SolutionV-A802IndexAmmonium Thiocyanate,V-A28 Ammonium Thiocyanate Solution,V-A28Ammonium Thiocyanate VS,V-A142 Ammonium Vanadate Solution,V-A28 Ammonium Vanadate,see Ammonium MetavanadateAmobarbital,I-161Amobarbital Sodium,I-162Amomum fruit,IV-56Amorphous Organosilica Polymer, Octadecylsilyl,V-A98Amoxicillin and Potassium Clavulanate Injection,see Co-amoxiclav Injection Amoxicillin and Potassium Clavulanate Oral Suspension,see Co-amoxiclav Oral SuspensionAmoxicillin and Potassium Clavulanate Tablets,Dispersible,see Dispersible Co-amoxiclav TabletsAmoxicillin and Potassium Clavulanate Tablets,see Co-amoxiclav Tablets Amoxicillin Capsules,III-138 Amoxicillin Injection,III-139 Amoxicillin Oral Suspension,III-141 Amoxicillin Sodium,I-163,V-S9 Amoxicillin Sodium for Injection,III-139Amoxicillin Trihydrate,I-165,V-S9,V-A28Ampere,Definition of,I-32,II-32,III-32,IV-32,V-32 Amperometric,Potentiometric and Voltametric Titrations,V-280 Amperometric Titration,V-280 Amphotericin,I-168Amphotericin B see Amphotericin Amphotericin for Infusion,III-142 Amphotericin Lozenges,I-xxix Amphotericin Oral Suspension,I-xxix Ampicillin,I-170Ampicillin Capsules,III-143Ampicillin Capsules,Flucloxacillin and, see Co-fluampicil CapsulesAmpicillin Injection,III-144Ampicillin Oral Suspension,III-146 Ampicillin Oral Suspension, Flucloxacillin and,see Co-fluampicil Oral SuspensionAmpicillin Sodium,I-172,V-S10 Ampicillin Sodium for Injection,III-144 Ampicillin Trihydrate,I-175,V-S10 Amyl Acetate,V-A28Amyl Alcohol,see Isoamyl Alcohola-Amylase,V-A28a-Amylase Solution,V-A28 Amylmetacresol,I-178,V-S10Amylose-derivative Silica Gel for Chromatography,V-A115b-Amyrin,V-A28Anacardium for Homoeopathic Preparations,IV-428Anaesthetic Ether,I-902Analytical Procedures,Validation of,V-673Analytical Sieving,Particle-size Distribution Estimation By,V-503 Anastrozole,I-179cis-Anethole,V-A28Anethum Graveolens L.Sowa Group,seeAnethum Graveolens Sowa Fruit,Anethum Graveolens Sowa Fruit,IV-58Angelica Archangelica Root,IV-59Angelica Dahurica Root,IV-60Angelica Pubescens Root,IV-62Angelica Sinensis Root,IV-63Angelica Sinensis Root,see ProcessedAngelica Sinensis RootAnhydrous Acetic Acid,V-A20Anhydrous Aluminium Oxide,V-A23Anhydrous Ampicilin see AmpicillinAnhydrous Azapropazone,V-S12Anhydrous Beclometasone Dipropionate,I-239Anhydrous Caffeine,see CaffeineAnhydrous Calcipotriol,I-353Anhydrous Calcium Acetate,see CalciumAcetateAnhydrous Calcium Chloride,V-A37Anhydrous Calcium Gluconate,I-372Anhydrous Calcium HydrogenPhosphate,I-377Anhydrous Calcium Lactate,I-378Anhydrous Chlorobutanol,I-518Anhydrous Citric Acid,I-569,V-A45Anhydrous Copper Sulfate,I-647Anhydrous Disodium HydrogenOrthophosphate,V-A59Anhydrous Disodium HydrogenPhosphate,I-788Anhydrous Docetaxel,I-796Anhydrous Ephedrine,I-849Anhydrous Formic Acid,V-A67Anhydrous Glucose,I-1083Anhydrous Iron(III)Chloride,V-A77Anhydrous Lactose,II-66Anhydrous Lithium Metaborate,V-A81Anhydrous Magnesium Citrate,II-166Anhydrous Methanol,V-A85Anhydrous Morphine,V-A91Anhydrous Nevirapine,II-358Anhydrous Niclosamide,II-362Anhydrous Paroxetine Hydrochloride,II-504Anhydrous Phloroglucinol,II-566Anhydrous Pyridine,V-A110Anhydrous Silica Gel,V-A114Anhydrous Silica,HydrophobicColloidal,II-807Anhydrous Sodium Acetate,V-A120Anhydrous Sodium Carbonate,II-830,V-A121,V-A141Anhydrous Sodium DihydrogenOrthophosphate,V-A122Anhydrous Sodium DihydrogenPhosphate,II-839,V-A122Anhydrous Sodium Sulfate,II-872,V-A124Anhydrous Sodium Sulfite,II-873,V-A124Anhydrous Sodium Sulphate seeAnhydrous Sodium SulfateAnhydrous Sodium Sulphite seeAnhydrous Sodium SulfiteAnhydrous Torasemide,II-1066Anhydrous Valaciclovir Hydrochloride,II-1134Aniline,V-A28Aniline Hydrochloride,V-A28Aniline Hydrochloride Solution,V-A28Animal Spongiform EncephalopathyAgents Via Human and VeterinaryMedicinal Products,Minimising theRisk of Transmitting,V-611Animals,Use of,I-15,II-15,III-15,IV-15,V-15Anion Exchange Resin,V-A28Anion Exchange Resin forChromatography,Strongly Basic,V-A28Anion Exchange Resin R1,V-A28Anion Exchange Resin R2,V-A28Anion exchange resin R3,V-A29Anion Exchange Resin,Strongly Basic,V-A28Anion Exchange Resin,Weak,V-A29Anion-exchange Resin forChromatography,Strongly Basic R1,V-A28Anionic Emulsifying Wax,see EmulsifyingWaxAnisaldehyde,V-A29Anisaldehyde Solution,V-A29Anisaldehyde Solution R1,V-A29Anise Ketone,V-A29Anise Oil,IV-71Anise Water,Concentrated,IV-73Aniseed,IV-66Aniseed Oil,see Anise Oilp-Anisidine,V-A29Anisidine Value,V-326Anolyte for Isoelectric Focusing pH3to5,V-A29Antazoline Hydrochloride,I-181Anthracene,V-A29Anthranilic Acid,see2-Aminobenzoic AcidAnthrax,see Anthrax Vaccine for HumanUse(Adsorbed,Prepared from CultureFiltrates)Anthrax Vaccine for Human Use(Adsorbed,Prepared from CultureFiltrates),IV-527Anthrone,V-A29Anthrone Reagent,V-A29Antibiotics,Microbiological Assay of,V-396,V-655Antibiotics,Potency of,I-14,II-14,III-14,IV-14,V-14Anticoagulant and Preservative Solutionsfor Blood,IV-461Anti-D Immunoglobulin for IntravenousUse,IV-497Anti-D(Rh0)Immunoglobulin,IV-496Antimicrobial Preservation,Efficacy of,V-494,V-653Antithrombin III ConcentrateAnticomplimentary activity ofimmunoglobulin,Test for V-427Anti-D immunoglobulin,human,Assayof V-429Anti-D antibodies in humanimmunoglobulin V-431Anti-A and anti-B haemogglutininsV-432Antimicrobial Preservatives,Definition ofSuitable,I-11,II-11,III-11,IV-11,V-11Antimony Compounds,Reactions of,V-267page numbers in bold type relate to monograph titles Index V-A803。
Ibuprofen_15687-27-1_DataSheet_MedChemExpress
P d DSh Product Name:Ibuprofen CAS No.:15687-27-1Cat. No.:HY-78131Product Data SheetMWt:206.28Formula:C13H18O2Purity :>98%Solubility:DMSO 41 mg/mL (198 mM); Water<1/L (<1M)Mechanisms:Biological Activity:Ibuprofen (Motrin) is an anti-inflammatory inhibitor targeting COX-1 and COX-2, of which is used forPathways:Immunology/Inflammation; Target:COX <1 mg/mL (<1 mM)p ()y g gpain relief, fever reduction and for reducing swelling.Target: COX-1; COX-2 Ibuprofen (INN) is a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief, feverreduction, and for reducing swelling.Nonsteroidal anti-inflammatory drugs such as ibuprofen work by inhibiting the enzyme cyclooxygenase (COX), which converts arachidonic acid to prostaglandin H2(PGH2). PGH2, in turn, is converted by other enzymes to several other prostaglandins (which are mediators of pain, inflammation, and fever) and to thromboxane A2 (which stimulates plateletaggregation, leading to the formation of blood clots).Lik i i d i d th i ib f i l ti COX i hibit i th t it i hibit t References:[1]. Van Esch A, et al. Antipyretic efficacy of ibuprofen and acetaminophen in children with febrileseizures. Arch Pediatr Adolesc Med. 1995 Jun;149(6):632-7.[2]Rao P et al Evolution of nonsteroidal anti inflammatory drugs (NSAIDs):cyclooxygenase (COX)Like aspirin and indomethacin, ibuprofen is a nonselective COX inhibitor, in that it inhibits two isoforms of cyclooxygenase, COX-1 and COX-2. The analgesic, antipyret...[2]. Rao P, et al. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX)inhibition and beyond. J Pharm Pharm Sci. 2008 Sep 20;11(2):81s-110s.[3]. Kakuta H, et al. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-typecyclooxygenase-1 selective inhibitor. J Med Chem. 2008 Apr 24;51(8):2400-11.Caution: Not fully tested. For research purposes onlyMedchemexpress LLC18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
760-78-1_DL-正缬氨酸_MED11074技术资料_上海_Medbio脉铂
1g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11127
Fmoc-L-丝氨酸
Fmoc-Ser-OH
73724-45-5
100g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
CAS
包装
纯度
MedBio
MED11025
N-羟基琥珀酰亚胺
HOSu
6066-82-6
100g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11040
丝氨酸苄酯盐酸盐
H-Ser-OBzl.HCl
1738-72-3
100g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11086
5g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11059
N-Fmoc-N'-Boc-L-2,3-二氨基丙酸
Fmoc-Dap(Boc)-OH
162558-25-0
1g
≥98%
纯度
MedBio
MED11049
Fmoc-N-三苯甲基-L-天冬酰胺
Fmoc-Asn(Trt)-OH
132388-59-1
100g
≥98%
品牌
货号
中文名称
透析免疫沉淀试剂盒（50 次反应） （Pierce 交联 IP 试剂盒）说明书
说明书Pierce®交联 IP（免疫沉淀）试剂盒26147 2134.8货号描述26147 Pierce 交联 IP 试剂盒，包含足够进行 50 次免疫沉淀反应的试剂（每次使用 10 μL 树脂用于固定化抗体）试剂盒组分：Pierce 蛋白 A/G 加强型琼脂糖树脂，0.55 mL 固相树脂以 50%的浆液形式提供（例如，100 μL 50%的浆液含有 50 μL 固相树脂）。
20X交联缓冲液，25 mL，使用时稀释至1X，即为：0.01 M 磷酸钠盐缓冲液，0.15 M NaCl；pH 7.2 溶液DSS （辛二酸二琥珀酰亚胺酯），No-Weigh™（免称重）式，8X2mg 微管包装IP 裂解/洗涤缓冲液，2 X 50 mL，0.025 M Tris，0.15 M NaCl，0.001 M EDTA，1% NP-40，5%甘油；pH 7.4100X条件缓冲液，5 mL，中性 pH 缓冲液20XTris-缓冲盐溶液，25 mL，使用时稀释至1X，即为 0.025 M Tris，0.15 M NaCl；pH 7.2溶液洗脱缓冲液，50 mL，pH 2.8，含有伯胺非还原型上样缓冲液，（5X），5 mL，0.3M Tris•HCl，5% SDS，50%甘油，泳道标记示踪染料；pH 6.8Pierce 离心柱-带螺旋盖，100 个柱子，且包含相应配件微量离心收集管，2 mL，100 个微量离心样品管，1.5 mL，50 个Pierce 对照琼脂糖树脂（4％交联琼脂糖珠），2 mL 固相树脂以 50%的浆液形式提供（例如，100 μL 50%的浆液含有 50 μL 固相树脂）储存：收到试剂盒后将其储存于 4°C 。
DSS 置于 4°C 干燥保存。
试剂盒于室温运输。
产品简介Thermo Scienti c Pierce 交联 IP 试剂盒通过将抗体共价交联于蛋白 A/G 树脂从而高效地实现抗原免疫沉淀反应。
GLP类似物药物进展
G L P-1类似物药物进展-截止胰高血糖素样肽（glucagon-likepeptide，GLP）是小肠表皮细胞在食物刺激情况下分泌的单肽类肠促胰岛素，包括GLP-1、GLP-2两种类型。
其中GLP-2具有促进小肠生长，抑制细胞凋亡，促进胃排空，增加食欲的药理作用，临床上可用于治疗小肠短小综合症；而GLP-1具有促进胰岛素分泌，保护胰岛β细胞，抑制胰高血糖素分泌，抑制胃排空，降低食欲的药理作用，临床可用于二型糖尿病和肥胖症的治疗。
人体内具有生物活性的GLP-1主要是GLP-1（7-36）酰胺和GLP-1（7-37），天然GLP-1可被二肽基肽酶Ⅳ（dipeptidylpeptidase-Ⅳ,DPP-Ⅳ）迅速水解失活（半衰期小于5min），不具有临床使用价值，因此对GLP-1结构修饰，掩盖DPP-Ⅳ的结合位点，延长半衰期并保证疗效是该类药物研发的主要方向。
一、已上市GLP-1类似物目前已上市的5个GLP-1类似物（表1）包括艾塞那肽(Byetta/Bydureon,byAmylin/Lilly)、利拉鲁肽(Victoza/Saxenda,byNovoNordisk)、利司那肽(Lyxumia,bySanofiAventis/Zealand)、阿必鲁肽(Tanzeum,byGSK)及杜拉鲁肽(Trulicity,byLilly)：1.艾塞那肽（Exenatide）艾塞那肽（商品名Byetta）是第一个上市的GLP-1类似物，由Amylin和Lilly公司于1995年开始联合研发，2005年4月获得FDA的批准上市。
艾塞那肽源于从蜥蜴唾液中分离出的GLP-1类似物Exendin-4，与GLP-1大约有53%的同源性。
由于其N端第二位由Gly代替了GLP-1中Ala，不被DPP-Ⅳ降解，而相对天然GLP-1而言具有较长的半衰期和较强的生物活性，临床使用频率为每日2次。
AstraZeneca收购Amylin取得艾塞那肽的全球开发销售权后，开发了其缓释混悬制剂BydureonPen，并于2014年获得FDA批准。
二甲双胍联合顺铂对黑色素瘤细胞的抑制作用及其机制研究
任
煜
刘婷婷
安庆医药高等专科学校药学系
[摘
要] 目的
刘慧娟
严其高 ①
任丽英
安徽安庆 246052;① 教务处
探讨二甲双胍联合顺铂对黑色素瘤细胞的抑制作用及机制。方法
小鼠恶性黑色素
瘤细胞 B16,设空白组、对照组、给药组 A、给药组 B、给药组 C、给药组 D、给药 E 组。给药 A、
B、
C、
D、
nh
i
b
i
t
o
r
f
f
e
c
to
fme
t
f
o
rmi
nc
omb
i
ne
dwi
t
hc
i
s
l
a
t
i
non me
l
anomac
e
l
l
sandi
t
sapop
t
o
s
i
s
ye
p
me
chan
i
sm QIBi
ngj
i
e,
REN Yu,
LIU Ti
ngt
i
ng,
e
ta
l(
Depar
tmen
tof Pharmacy,Anq
i
ng Medi
顺铂混合物(
20μL)室 温 处 理 24h,具 体 给 药 浓
度见表 1。
表 1 二甲双胍联合顺铂对恶性黑色素瘤细胞 B16 增殖的抑制作用(
x±s)
0
/L)
顺铂(
l
μmo
0
给药组 B
2.
布洛芬 有关物质 薄层
布洛芬有关物质薄层摘要：1.布洛芬的基本信息2.布洛芬的相关物质3.薄层色谱法在布洛芬分析中的应用正文：布洛芬（Ibuprofen）是一种非处方药，属于非甾体抗炎药（NSAIDs）类药物，广泛应用于缓解轻至中度疼痛、降低发热和消炎等方面。
其化学名称为2-(4-异丙基苯基)丙酸，化学式为C13H18O2。
布洛芬具有良好的药理作用和广泛的临床应用，但在生产和储存过程中可能会产生一些相关的杂质，这些杂质对药物的安全性和有效性具有重要影响。
布洛芬的相关物质主要包括两个方面：1.生产过程中的副产物，如异丙基苯酚、对异丙基苯酚等。
这些副产物可能由于生产工艺、反应条件等因素而产生。
2.储存过程中产生的降解产物，如布洛芬酸、4-异丙基苯酚等。
这些降解产物可能由于光照、高温、湿度等环境因素影响而导致布洛芬质量变化。
为了确保布洛芬的质量和安全性，需要对其中的相关物质进行分析和控制。
薄层色谱法（Thin Layer Chromatography，TLC）是一种常用的药物分析方法，具有操作简便、分离效果好、灵敏度高等优点。
在布洛芬的相关物质分析中，薄层色谱法可以有效地实现对杂质成分的定性、定量分析。
具体操作过程如下：1.制备薄层板：选用合适的固定相和流动相，将二者按一定比例涂布在玻璃板上，干燥后备用。
2.样品处理：将布洛芬样品进行粉碎、提取、浓缩等处理，获得待测样品溶液。
3.点样：将待测样品溶液分别点在薄层板上，形成斑点。
4.展开：将薄层板放入展开槽中，加入流动相，展开一定时间。
5.显色：将薄层板放入显色槽中，加入显色剂，显色一定时间。
6.观察：用紫外灯或碘蒸气对薄层板进行观察，分析布洛芬样品中的相关物质。
综上所述，布洛芬作为一种广泛应用的药物，其相关物质分析是保证药物质量和安全性的重要环节。
ibuprofen Gel 英国药典
British Pharmacopoeia Volume IIIFormulated Preparations: Specific MonographsIbuprofen GelGeneral NoticesAction and useCyclo-oxygenase inhibitor; analgesic; anti-inflammatory.DEFINITIONIbuprofen Gel is a solution of Ibuprofen in a suitable water-miscible basis.The gel complies with the requirements stated under Topical Semi-solid Preparations and with the following requirements. Content of ibuprofen, C13H18O295.0 to 105.0% of the stated amount.IDENTIFICATIONA. Carry out the method for thin-layer chromatography , Appendix III A, using the following solutions.(1) Shake vigorously a quantity of the gel containing 0.125 g of Ibuprofen with 25 ml of dichloromethane for 5 minutes and use the upper layer.(2) 0.5% w/v of ibuprofen BPCRS in dichloromethane .CHROMATOGRAPHIC CONDITIONS(a) Use as the coating silica gel H .(b) Use the mobile phase as described below.(c) Apply 5 µl of each solution.(d) Develop the plate to 10 cm.(e) After removal of the plate, dry it at 120° for 30 minutes, lightly spray the plate with a 1% w/v solution of potassium permanganate in 1M sulphuric acid , heat at 120° for 20 minutes and examine under ultraviolet light (365 nm).MOBILE PHASE5 volumes of anhydrous acetic acid , 25 volumes of ethyl acetate and 75 volumes of n-hexane.CONFIRMATIONThe principal spot in the chromatogram obtained with solution (1) corresponds in position and colour to that in the chromatogram obtained with solution (2).B. In the Assay the retention time of the principal peak in the chromatogram obtained with solution (1) is the same as that of the principal peak in the chromatogram obtained with solution (2).TESTRelated substancesCarry out the method for liquid chromatography , Appendix III D, using the following solutions.(1) Disperse a quantity of the gel containing 0.1 g of Ibuprofen in 25 ml of warm methanol , cool and dilute to 50 ml with methanol .(2) Dilute 1 volume of solution (1) to 100 volumes with methanol .(3) Dissolve 50 mg of ibuprofen BPCRS in 2.5 ml of a 0.006% w/v solution of Ibuprofen Impurity B EPCRS in methanol (prepared by diluting 1 volume of Ibuprofen Impurity B EPCRS to 10 volumes with methanol ) and add sufficient methanol to produce 25 ml.CHROMATOGRAPHIC CONDITIONS(a) Use a stainless steel column (15 cm × 4.6 mm) packed with end-capped octadecylsilyl silica gel for chromatography (5 µm) (Spherisorb ODS 2 is suitable).(b) Use isocratic elution and the mobile phase described below.(c) Use a flow rate of 2 ml per minute.(d) Use an ambient column temperature.(e) Use a detection wavelength of 214 nm.(f) Inject 20 µl of each solution.(g) Equilibrate the column with the mobile phase for about 45 minutes before starting the chromatography.(h) Allow the chromatography to proceed for 1.5 times the retention time of the principal peak. When the chromatograms are recorded under the conditions described above, the retention time of ibuprofen is about 20 minutes.MOBILE PHASE0.5 volume of orthophosphoric acid , 340 volumes of acetonitrile and 600 volumes of water diluted to 1000 volumes with water. Equilibrate the column with the mobile phase for about 45 minutes before starting the chromatography.SYSTEM SUITABILITYIn the chromatogram obtained with solution (3) measure the height (a) of the peak due to 2-(4-butylphenyl)-propionic acid and the height (b) of the lowest point of the curve separating this peak from that due to ibuprofen. The test is not valid unless a is greater than 1.5b. If necessary, adjust the concentration of acetonitrile in the mobile phase to obtain the required resolution.LIMITSIn the chromatogram obtained with solution (1):the area of any peak corresponding to ibuprofen impurity B is not greater than the area of the corresponding peak in the chromatogram obtained with solution (3) (0.3%);the area of any other secondary peak is not greater than 0.3 times the area of the principal peak in the chromatogram obtained with solution (2) (0.3%);the sum of the area of any secondary peaks , other than the peak due to impurity B, is not greater than 0.7 times the area of the principal peak in the chromatogram obtained with solution (2) (0.7%).Disregard any peak the area of which is less than 0.1 times the area of the principal peak in the chromatogram obtained with solution (2) (0.1%).ASSAYCarry out the method for liquid chromatography , Appendix III D, using the following solutions.(1) Disperse a quantity of the gel containing 50 mg of Ibuprofen with 50 ml of warm methanol for 10 minutes, cool and add sufficient methanol to produce 100 ml. Dilute 10 volumes of this solution to 20 volumes with the mobile phase.(2) Dilute 10 volumes of a solution containing 0.05% w/v of ibuprofen BPCRS in methanol to 20 volumes with the mobile phase.CHROMATOGRAPHIC CONDITIONS(a) Use a stainless steel column (25 cm × 4.6 mm) packed with end-capped octadecylsilyl silica gel for chromatography (10µm) (Nucleosil C18 is suitable).(b) Use isocratic elution and the mobile phase described below.(c) Use a flow rate of 1.5 ml per minute.(d) Use an ambient column temperature.(e) Use a detection wavelength of 264 nm.(f) Inject 20 µl of each solution.MOBILE PHASE3 volumes of orthophosphoric acid , 247 volumes of water and 750 volumes of methanol .DETERMINATION OF CONTENTCalculate the content of C13H18O2 using the declared content of C13H18O2 in ibuprofen BPCRS .IMPURITIESThe impurities limited by the requirements of this monograph include:1. (2RS)-2-(4-butylphenyl)propanoic acid (Ibuprofen Impurity B).© Crown Copyright 2009。
Western及IP细胞裂解液(无抑制剂)
版本：A3 修改日期：2023.12.12 Western 及IP 细胞裂解液(无抑制剂)产品简介：多种成分均可以从细胞中提取总蛋白，如Triton 、SDS 、NP-40等，Western 及IP 细胞裂解液是采用一种非变性裂解方法来裂解细胞，并获得总蛋白的裂解液，所获得的蛋白质可以用于PAGE 电泳，Western ，免疫沉淀(Immunol Precipitation,IP)和免疫共沉淀(co-IP)等，主要由Tris-HCl 、NaCl 、低浓度Triton X-100， 低浓度sodium pyrophosphate 等组成，不含蛋白酶、磷酸酶抑制剂，并维持原有的蛋白间相互作用。
用Western 及IP 细胞裂解液(无抑制剂)(Cell lysis buffer for Western and IP without inhibitors)得到的蛋白，可以用BCA 蛋白定量试剂盒测定蛋白浓度，由于含有较高浓度的Triton X-100等干扰物质，不宜用Bradford 法测定由Western 及IP 细胞裂解液获得样本的蛋白浓度。
该试剂仅用于科研领域，不适用于临床诊断或其他用途。
产品组成：操作步骤(仅供参考)：(一)贴壁培养细胞1、 取Western 及IP 细胞裂解液室温溶解混匀，根据需要选择添加或不添加蛋白酶抑制剂。
2、 去除贴壁细胞的培养液，用PBS 、NS 或无血清培养液清洗1次，低速离心，弃上清，留取沉淀。
3、 按照6孔板每孔加入100～200μl 裂解液的比例，加入Western 及IP 细胞裂解液。
移液器轻轻吹打，使裂解液和细胞充分接触；通常裂解液作用于细胞1～5s 内，细胞就会被裂解。
4、 10000～12000g ，离心 (如果用冷冻离心机4℃离心效果更佳)，取上清。
5、 进行后续的SDS-PAGE 、Western 、免疫沉淀和免疫共沉淀等操作。
(二)悬浮培养细胞1、 取Western 及IP 细胞裂解液室温溶解混匀，根据需要选择添加或不添加蛋白酶抑制剂。
普利莱基因技术膜再生液说明书
北京普利莱基因技术有限公司电话：************62053186 Email:************************膜再生液(Stripping Solution) P1650描述：膜再生液，也称做抗体剥离液体、一抗二抗去除液。
允许对同一张膜进行多次Western Blot检测。
在室温条件下，将用过的膜浸泡在膜再生液中30分钟，能够选择性清除与膜抗原结合的第一抗体及第二抗体，但不影响电转移到膜上的蛋白。
随后可以使用不同的抗体进行下一轮Western Blot实验，可利用同一张膜进行多次蛋白检测。
不仅适宜用少量样品多次检测多种不同蛋白，即使样品量并不匮乏，采用这种多次检测同一张膜上的蛋白的策略，能省去给药处理、蛋白电泳和膜转移等耗费性步骤。
特点：（1）无毒无味无害，室温保存和使用；（2）可对同一张膜进行10次以上的Western Blot检测。
适用：硝酸纤维素膜或PVDF膜。
使用前膜可以保存在PBS或TBS缓冲液，也可以室温干燥保存数月。
干的PVDF 膜应该先用甲醇泡5分钟。
安全性：无毒无味。
按照普通化学品安全规范进行操作和处置。
储存：室温保存，一年有效。
温度过低可能出现浑浊。
操作步骤：1.将膜充分浸泡于适当体积的再生液中，室温孵育15~30分钟并不时晃动。
孵育时间的长短应参考后面的说明进行优化。
洗脱某些抗体需要较长的时间如30~60分钟。
2.用镊子取出膜，用自备Western Blot洗涤缓冲液或普利莱封闭洗涤缓冲液（B1009）淋洗膜一次，再洗膜5分钟。
3.此时膜上抗体已去除，膜已再生。
用脱脂奶粉或BSA封闭，进行下一轮Western Blot实验。
说明:1. 膜再生或Stripping的实质是在不影响膜上结合的抗原的条件下，将与抗原分子结合的一抗和二抗洗脱下来。
有许多因素影响抗体从膜上的洗脱，如膜的类型、抗体类型和浓度及其与抗原结合特性等。
按下面的说明优化再生液中孵育膜的时间至关重要。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
P d D
Sh Product Name:
Ibuprofen CAS No.:
15687-27-1Cat. No.:
HY-78131Product Data Sheet
MWt:
206.28Formula:
C13H18O2Purity :>98%
Solubility:DMSO 41 mg/mL (198 mM); Water
<1/L (<1
M)
Mechanisms:
Biological Activity:
Ibuprofen (Motrin) is an anti-inflammatory inhibitor targeting COX-1 and COX-2, of which is used for
Pathways:Immunology/Inflammation; Target:COX <1 mg/mL (<1 mM)p ()y g g
pain relief, fever reduction and for reducing swelling.
Target: COX-1; COX-2 Ibuprofen (INN) is a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief, fever
reduction, and for reducing swelling.Nonsteroidal anti-inflammatory drugs such as ibuprofen work by inhibiting the enzyme cyclooxygenase (COX), which converts arachidonic acid to prostaglandin H2(PGH2). PGH2, in turn, is converted by other enzymes to several other prostaglandins (which are mediators of pain, inflammation, and fever) and to thromboxane A2 (which stimulates platelet
aggregation, leading to the formation of blood clots).Lik i i d i d th i ib f i l ti COX i hibit i th t it i hibit t References:
[1]. Van Esch A, et al. Antipyretic efficacy of ibuprofen and acetaminophen in children with febrile
seizures. Arch Pediatr Adolesc Med. 1995 Jun;149(6):632-7.[2]Rao P et al Evolution of nonsteroidal anti inflammatory drugs (NSAIDs):cyclooxygenase (COX)Like aspirin and indomethacin, ibuprofen is a nonselective COX inhibitor, in that it inhibits two isoforms of cyclooxygenase, COX-1 and COX-2. The analgesic, antipyret...
[2]. Rao P, et al. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX)
inhibition and beyond. J Pharm Pharm Sci. 2008 Sep 20;11(2):81s-110s.[3]. Kakuta H, et al. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type
cyclooxygenase-1 selective inhibitor. J Med Chem. 2008 Apr 24;51(8):2400-11.Caution: Not fully tested. For research purposes only
Medchemexpress LLC
18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。